# Axoltis Pharma

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/axoltis-pharma

- Industry: Pharmaceuticals
- Headquarters: Clermont-Ferrand, France
- Website: www.axoltis.com/
- Total disclosed funding: $6.3M
- Latest round: Series A (Nov 2, 2025)
- Investors on record: 4

## About

Based in Clermont-Ferrand, France, Axoltis Pharma is focused on developing innovative therapeutics to address challenges in treating neurological disorders.Axoltis Pharma is a biotechnology company that concentrates on creating therapeutic solutions for degenerative and traumatic neurological conditions. The firm was recently active in raising EUR 18.000 mn in a SERIES A funding round on November 2, 2025, after previously securing a total of EUR 18.000 mn. The company has completed one deal to date.Axoltis specializes in developing innovative therapeutics aimed at addressing significant challenges in the treatment of degenerative and traumatic neurological disorders. The company’s flagship product, NX210c, is an advanced therapeutic peptide designed to enhance recovery and improve the functionality and quality of life for patients suffering from these conditions. NX210c targets high unmet medical needs in the neurological space, specifically focusing on conditions that require immediate and effective intervention. The primary end users of Axoltis’s products are healthcare providers who treat patients with these disorders, particularly in regions with limited therapeutic options. The company operates in various geographical markets, ensuring that its innovative solutions reach a diverse patient population globally.Axoltis's revenue model is centered around the commercialization of its novel therapeutic product, NX210c, through strategic partnerships and collaborations with healthcare providers and institutions. Revenue is generated primarily from direct sales to hospitals and clinics, where the product is prescribed to patients with specific neurological disorders. The company may also engage in collaborative research agreements, which can provide additional funding streams. Pricing structures are designed to reflect the value offered by NX210c in terms of improved patient outcomes, although specific pricing details are not disclosed. Transactions typically involve contract negotiations that establish terms for supply and distribution, ensuring that the therapeutic product is accessible to those in need while fostering long-term relationships with healthcare providers.Axoltis Pharma plans to leverage the EUR 18.000 mn raised in the SERIES A funding round to conduct Phase II trials for NX210c and to further develop its blood-brain barrier therapy. The company aims to expand its presence in various global markets, although specific regions targeted for expansion have not been detailed. The funding will support these advancements, helping to facilitate the introduction of innovative solutions aimed at addressing critical needs in neurological care.

## Funding rounds

- Series A, Nov 2, 2025 — FaDiese, Simba Santé, Cenitz
- Series D, Jul 24, 2020, $1.8M — Sofimac Partners, FaDiese
- Series D, May 3, 2019, $1.7M — Sofimac Partners, FaDiese
- Series C, Nov 28, 2017, $2.8M — Sofimac Partners, FaDiese

## Investors

- Sofimac Partners (https://capitalatlas.ai/funds/sofimac-partners) — Series C, Series D
- FaDiese (https://capitalatlas.ai/funds/fadiese) — Series C, Series D, Series A
- Simba Santé — Series A
- Cenitz (https://capitalatlas.ai/funds/cenitz) — Series A